Charles Schwab Investment Management Inc. Buys 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Charles Schwab Investment Management Inc. lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 484,797 shares of the company's stock after purchasing an additional 52,498 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.71% of Replimune Group worth $5,313,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Intech Investment Management LLC bought a new position in shares of Replimune Group during the 3rd quarter valued at about $252,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Replimune Group by 25.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,208 shares of the company's stock valued at $1,405,000 after acquiring an additional 25,939 shares during the last quarter. LMR Partners LLP raised its stake in shares of Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company's stock worth $904,000 after acquiring an additional 48,920 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Replimune Group in the 3rd quarter worth approximately $222,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after purchasing an additional 5,926 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Stock Up 1.4 %

REPL stock traded up $0.17 on Friday, hitting $12.39. The company had a trading volume of 158,011 shares, compared to its average volume of 1,046,665. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The stock's 50-day simple moving average is $12.17 and its 200 day simple moving average is $10.40.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, research analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have weighed in on REPL shares. HC Wainwright reissued a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. BMO Capital Markets increased their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research report on Friday, November 22nd. Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock. Finally, Roth Capital upgraded Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $17.29.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.